Biohaven Pharmaceutical Holding Co Ltd (BHVN NYSE) stock market data APIs
$8.7086
0.27(3.1%)
as of May 15, 2026
Try our APIs with
free plan!
Biohaven Pharmaceutical Holding Co Ltd Financial Data Overview
Price chart is built with
Anychart
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Prev. Close
8.7086
Open
8.9771
High
8.9967
Low
8.5335
52 wk Range
7.48-18.566
Market Cap
1 319 M
Shares Outstanding
151 M
EPS
-0.69
Beta
3.311
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Biohaven Pharmaceutical Holding Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biohaven Pharmaceutical Holding Co Ltd data using free add-ons & libraries
Get Biohaven Pharmaceutical Holding Co Ltd Fundamental Data
Biohaven Pharmaceutical Holding Co Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -607 192 128
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Biohaven Pharmaceutical Holding Co Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-08
- EPS/Forecast: -1.04
Get Biohaven Pharmaceutical Holding Co Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biohaven Pharmaceutical Holding Co Ltd News
New
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's Changed
Biohaven reported first-quarter 2026 results with a net loss of US$130.53 million, narrower than a year earlier, and simultaneously filed a mixed shelf registration covering equity, debt, and other se...
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Biohaven Ltd. (BHVN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the m...
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why Biohaven’s latest ear...
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Pi...
Get Biohaven Pharmaceutical Holding Co Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
